MedImmune to close vaccines sites in California

Tuesday, July 17, 2012 02:55 PM

Gaithersburg, Md.-based MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, closing its Mountain View, Calif., and Santa Clara, Calif., sites and consolidating its infectious disease and vaccines R&D to other existing sites. The changes are expected to be completed in 2014.

MedImmune's Hayward, Calif., site will remain open with additional capabilities invested in it.

MedImmune said the changes will enhance innovation across its therapeutic areas and improve alignment with other areas of product development while reducing the fixed costs associated with the sites.

The company estimates that approximately 300 positions will be affected. Of those, approximately 100 positions will move to other MedImmune locations. Worldwide, MedImmune has approximately 3,500 employees.

In February 2012, AstraZeneca announced an efficiency program to improve productivity, foster innovation and strengthen the company's commercial, operations and R&D capabilities, which runs through 2014.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 13

New partnership of Parkinson's groups aims to unify the message about importance of trial participation

Using study startup checklists can improve site-sponsor communication, relationships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs